Table 1 Chemoradiotherapy regimens for stage IE/IIE nasal extranodal NK/T cell lymphoma
From: Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
Regimen | Number | Drugs | RT | CR | G3/4 neutropenia | PFS |
|---|---|---|---|---|---|---|
Concurrent chemoradiotherapy | ||||||
 Simultaneous application of chemotherapy and radiotherapy | ||||||
DeVIC [20] | 27 | Dexamethasone, etoposide, ifosfamide, carboplatin | 50 Gy | 77% | 90.9% | 5-year 67% |
ESHAP [22] | 13 | Etoposide, steroid, Ara-C, cisplatin | 40 Gy | 92% | 92% | 2-year 72% |
DEP/DVIP [23] | 33 | Dexamethasone, etoposide, and cisplatin/dexamethasone, etoposide, ifosfamide, and cisplatin | 50.4 Gy | 63% | 85% | 5-year 60% |
 Weekly cisplatin with radiotherapy followed by chemotherapy | ||||||
VIPD [24] | 30 | Etoposide, ifosfamide, cisplatin, dexamethasone | 40–52.8 Gy | 80% | 46.7% | 3-year 85% |
VIDL [25] | 30 | Etoposide, ifosfamide, dexamethasone, L-asparaginase | 40–44 Gy | 87% | 80% | 5-year 73% |
MIDLE [26] | 28 | Methotrexate, ifosfamide, dexamethasone, L-asparaginase, etoposide | 36–44 Gy | 82% | 91.3% | 3-year 74% |
GDP [27] | 32 | Gemcitabine, dexamethasone and cisplatin | 56 Gy | 84.4% | 41% | 3-year 84% |
 Sequential chemoradiotherapy | ||||||
SMILE [29] | 17 | Dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide | >  40 Gy | 69% | n.a. | n.a. |
DICE-L [31] | 33 | Cisplatin, ifosfamide, etoposide, dexamethasone, L-asparaginase | 45 Gy | 90.9% | n.a. | 5-year 89% |
 Sandwich chemoradiotherapy | ||||||
GELOX/PGEMOX [32] | 27 | Gemcitabine, L-asparaginase, oxaliplatin/pegaspargase, gemcitabine, oxaliplatin | 56 Gy | 74.1% | 33.3% | 2-year 86% |
GELOXD/GEMOXD [35] | 167 | Gemcitabine, L-asparaginase, oxaliplatin, dexamethasone/pegaspargase, gemcitabine, oxaliplatin, dexamethasone | 50 Gy | 88.6% | 23.4%** | 3-year 72.8% |